GWM
VTVT icon

Geneos Wealth Management’s vTv Therapeutics VTVT Stock Holding History

Geneos Wealth Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25
Closed -$1K – 3013
2020
Q3 		$1K Buy
+25
New +$2.2K ﹤0.01% 2584
2020
Q1 		– Sell
-63
Closed -$4K – 2615
2019
Q4 		$4K Sell
63
-25
-28% -$1.52K ﹤0.01% 2266
2019
Q3 		$5K Hold
88
– – ﹤0.01% 2121
2019
Q2 		$5K Hold
88
– – ﹤0.01% 2136
2019
Q1 		$5K Hold
88
– – ﹤0.01% 2061
2018
Q4 		$7K Sell
88
-37
-30% -$3.42K ﹤0.01% 1903
2018
Q3 		$3K Hold
125
– – ﹤0.01% 2212
2018
Q2 		$7K Buy
+125
New +$9.23K ﹤0.01% 1851

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Geneos Wealth Management's VTVT Position: Q4 2020 in Review

Geneos Wealth Management sold out of vTv Therapeutics (VTVT) in Q4 2020, closing a stake of 25 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in VTVT in Q2 2018 and held it in 8 quarters. The position peaked at $7K in Q4 2018. 44 funds tracked by Wall St. Rank hold VTVT as of Q4 2020.

  • Geneos Wealth Management reported no remaining vTv Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 25 vTv Therapeutics shares in Q4 2020, an estimated $1K.
  • Geneos Wealth Management first reported a position in vTv Therapeutics in Q2 2018 and held it in 8 quarters.
  • Geneos Wealth Management's vTv Therapeutics position peaked at $7K in Q4 2018.
  • 44 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.